NCT03348163View on ClinicalTrials.gov

(mo)BETTA Trial in Transwomen for Optimization of ART

PHASE4TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 6, 2018

Primary Completion Date

December 15, 2020

Study Completion Date

December 15, 2020

Conditions
HIV Infections
Interventions
DRUG

B/FTC/TAF

B/FTC/TAF is bictegravir + tenofovir alafenamide + emtricitabine in one pill (single tablet regimen)

DRUG

Current ART

Current ART is emtricitabine plus tenofovir disoproxil fumarate or tenofovir alafenamide plus 3rd agent.

Trial Locations (1)

77009

Thomas Street Health Center, Houston

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

The University of Texas Health Science Center, Houston

OTHER

NCT03348163 - (mo)BETTA Trial in Transwomen for Optimization of ART | Biotech Hunter | Biotech Hunter